HCG Manavata Ties Up with Qure.ai to Boost AI-Driven Lung Disease Detection

The deployment is part of Qure.ai’s ongoing collaboration with Johnson & Johnson MedTech to expand AI-driven lung health solutions across India.

HCG Manavata Cancer Centre (HCGMCC) has announced a partnership with healthtech innovator Qure.ai to deploy AI-powered imaging solutions to improve early detection and structured management of lung diseases, including suspected lung cancer.

As part of the collaboration, Qure.ai’s qXR (AI-enabled Chest X-ray) and qCT (AI-enabled Chest CT) will be deployed at the hospital, supported by qTrack, the company’s disease tracking platform.

The technology facilitates real-time risk identification and automated triaging to enhance accuracy and speed of diagnosis.

Further, the deployment is part of Qure.ai’s ongoing collaboration with Johnson & Johnson MedTech to expand AI-driven lung health solutions across India.

“A 5 mm nodule missed today becomes stage-four cancer tomorrow. Qure.ai’s AI acts as our 24/7 digital sentinel catching whispers of disease before symptoms scream. This collaboration allows us to expand the boundaries of what’s possible in early detection,” said Prof Dr Raj Nagarkar, Chief of Surgical Oncology & Robotic Services and Managing Director, KIMS Manavata Hospitals, HCG Manavata Cancer Centre and Six Sigma, Nashik.

HCGMCC has also launched a dedicated Incidental Pulmonary Nodule (IPN) Clinic to serve as a central hub in a hub-and-spoke model for the region.

The clinic will support structured follow-up of high-risk imaging findings, enable timely intervention, and improve patient outcomes, particularly in early-stage lung cancer, where detection is often delayed.

“With this alliance, we are setting a precedent for how AI, robotics and next gen therapies can converge in a regional setting to build India’s future-ready oncology ecosystem,” Dr Nagarkar added.

Over the last year, HCGMCC has advanced research and treatment through initiatives such as developing a blood test capable of detecting 30 different cancers with 98.4 per cent accuracy, published in Cancer Reports. It has also established a Centre of Excellence in Cell and Gene Therapy, bringing therapies such as CAR-T cell treatment to non-metro regions.

“Our mission is to make the most advanced cancer care accessible to everyone and not just in big cities, but across regions around Nashik. Whether it's AI, cell and gene therapies or robotic precision surgery, we are bringing the future of oncology to patients today,” Dr Nagarkar said.

Stay tuned for more such updates on Digital Health News